MedPath

Assessment of the tolerance and safety of Prescription of different doses of Psilocybin in Healthy adults.

Phase 1
Conditions
depression
F03.600
Registration Number
RBR-37qx63d
Lead Sponsor
Biocase Brasil
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Adults without comorbidities aged between 21 and 65 years from both gender

Exclusion Criteria

Participants who meet any of the following exclusion criteria are not eligible for the study including use of medications that may interfere with the study drug, history of heart, liver, kidney disease, history of cancer or organ transplant, insulin dependent diabetes or uncontrolled diabetes, gastrointestinal disease that may interfere with the absorption of the substance orally, current or past history of psychiatric disorders as schizophrenia, psychotic disorder, bipolar disorder, personality disorder, first degree family history of psychiatric disorders, seizures or fainting, creatinine elevation, nicotine dependence that would prevent an individual from being nicotine-free for 7 to 10 hours during the dosing period, women who are pregnant or intending to become pregnant during the study or who are currently breastfeeding, chemical dependency or abuse of alcohol or illicit drugs in the last 12 months, platelets disorders, clinically significant anemia, liver injury

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath